Sequenom has appointed Myla Lai-Goldman to its board of directors and to the board's science committee. Lai-Goldman is a managing partner at Personalized Science and CEO of GeneCentric Diagnostics. Previously, she served as executive vice president, chief medical officer, and chief scientific officer at Laboratory Corporation of America.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.